期刊
EMBO JOURNAL
卷 25, 期 12, 页码 2686-2697出版社
WILEY
DOI: 10.1038/sj.emboj.7601173
关键词
fibrinolysis; plasma kallikrein; plasmin; uPA-; tPA- and plasminogen-deficient mice; wound healing
资金
- NCI NIH HHS [P01 CA072006] Funding Source: Medline
Simultaneous ablation of the two known activators of plasminogen ( Plg), urokinase-type ( uPA) and the tissue-type ( tPA), results in a substantial delay in skin wound healing. However, wound closure and epidermal re-epithelialization are significantly less impaired in uPA; tPA double-deficient mice than in Plg-deficient mice. Skin wounds in uPA; tPA-deficient mice treated with the broad-spectrum matrix metalloproteinase ( MMP) inhibitor galardin ( N-[( 2R)-2-( hydroxamido-carbonylmethyl)-4-methylpentanoyl]L-tryptophan methylamide) eventually heal, whereas skin wounds in galardin-treated Plg-deficient mice do not heal. Furthermore, plasmin is biochemically detectable in wound extracts from uPA; tPA double-deficient mice. In vivo administration of a plasma kallikrein ( pKal)-selective form of the serine protease inhibitor ecotin exacerbates the healing impairment of uPA; tPA double-deficient wounds to a degree indistinguishable from that observed in Plgdeficient mice, and completely blocks the activity of pKal, but not uPA and tPA in wound extracts. These findings demonstrate that an additional plasminogen activator provides sufficient plasmin activity to sustain the healing process albeit at decreased speed in the absence of uPA, tPA and galardin-sensitive MMPs and suggest that pKal plays a role in plasmin generation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据